CTLA4 and melanoma: In a preclinical model of melanoma, Twyman-Saint Victor et al. found that the resistance to RT plus anti-CTLA-4 was due to T-cell exhaustion, notably mediated by PD-1/PD-L1 axis activation with an upregulation of PD-L1 on melanoma cells.